Neo-Advent Technologies (NAT) is a privately held company headquartered in Marlborough, MA, with its facility in Littleton, MA. It was founded in 2003 by of accomplished scientists with diverse backgrounds who are committed to developing innovative technologies into commercially viable products. Our founders have decades of experience in drug formulation, small molecule synthesis, polymer synthesis, cosmetics, material sciences, and biology. NAT provides an extensive set of services to industry, academia and the government.
NAT identifies specialty needs in the marketplace and matches theose needs with the latest technology. We can take projects from concept to final product. To learn how we can help you with your technical challenges, please contact us.
“We tried many drug formulators across the country and overseas, but could not reach target outcomes in our oncology animal models. At that critical time, the NAT team stepped in and played a pivotal role in quickly overhauling the program. Their effort allowed switching from IV to oral means of administration of poorly soluble drug candidates, led to success of decisive toxicology studies, and enabled our IND filings and ongoing early clinical programs in tumor patients.”
Sharon Shacham, Ph.D., CSO, President of R&D, Karyopharm Therapeutics
“NAT’s contribution had a significant impact on our late preclinical program and helped to pave a path to clinical trials. They have addressed many formulation problems in our solid dose form of the lead drug candidate that steered to a vastly improved PK profile and increased its bioavailability.“
Eli Kaplan, M.D., CEO, NovareMed
“VeroScience relies on NAT to assist with its drug formulation and delivery solutions for its lead molecules, and lately, for analytical services, too. The nature of our applications often requires very particular and precise timing for drug release from the finished product. NAT always makes it work, on time and on budget.“
Anthony H. Cincotta, Ph.D., President, VeroScience LLC
Nelson Landrau, Co-Founder, President, CEO
Mr. Landrau has over 20 years of experience in polymer and synthetic organic chemistry, materials sciences, and drug formulation. He is an experienced drug formulator with over 15 years of hands-on involvement in drug product development, related formulation, and CMC aspects of moving drug candidates form early preclinical studies into clinical development. He established an excellent track record in the design of advanced coatings and polymeric materials while working for Foster Miller and Nikos, where he conducted NASA- and DOD-award winning work. At those firms he received multiple patents and two NASA awards for novel thermoset plasticizers for polyimide resins and high temperature micron-sized polymer spheres. At Inotek Pharmaceuticals in Beverly, MA he was a key contributor in formulating a stable microsuspension of a glaucoma drug candidate that was critical for achieving a desired therapeutic outcome (at the time of this writing in Phase 3 clinical trials). Also at Inotek he spearheaded scale-up, analysis, separation, and formulation of the complicated isomeric mixture of porphyrin drug candidates tested for ischemia-reperfusion injury applications and funded by a multimillion-dollar NIH grant. He is co-inventor on 8 US patents. At NAT he serves as a PI and hands-on investigator on various drug formulation projects, including solid dose formulations, injectable and topical formulations. He is an expert in using high-energy equipment for reducing particle size and liposomal production.
Mr. Landrau holds a B.S. degree in Chemistry from the University of Massachusetts, Boston.
Alex Nivorozhkin, Ph.D., Co-Founder & Chief Operating Officer
Dr. Nivorozhkin is an entrepreneur and a team builder in the life sciences’ arena with vast experience and a track record in early technology transfer and development. He was a co-founding member of Boston BioCom, LLC, a biopharma company funded by a seed investment from Pfizer. Dr. Nivorozhkin gained substantial experience in the commercial aspects of drug discovery and development at Epix Medical and Inotek Pharmaceuticals, where he served as the Head of Medicinal Chemistry. He served as a Senior Program Manager at the Center for Integration of Medicine and Innovative Technologies (CIMIT) at Massachusetts General Hospital, and also at a consortium of Harvard Medical School-affiliated hospitals, Boston University, Draper Laboratory and MIT aimed at developing new medical devices; and as a Scientific Programs Officer at Sheldon and Miriam Adelson Medical Research Foundation. He is a co-inventor of several drug candidates that have advanced to clinical trials and late pre-clinical studies in the United States. He has co-authored over 60 scientific publications in different areas of chemistry, chemical biology, and material sciences, and he holds more than 20 patents.
Dr. Nivorozhkin earned a Ph.D. in Physical Organic Chemistry from Rostov University in Russia. He conducted his postdoctoral research at University Paris-Sud, France, and at the Department of Chemistry and Chemical Biology, Harvard University.
Ken Avery, Ph.D., Head of Analytical Services
Dr. Avery has over 20 years of experience in specialty chemicals, industrial enzymes, surfactants, and the pharma industry. He was trained as an organic chemist in natural product synthesis. He was a research scientist at Hampshire Chemicals Corp., developing manufacturing processes for specialty chemicals. Then he moved to the pharmaceutical industry, first serving as an enzyme and biocatalysis process chemist at Altus Pharmaceuticals, Cambridge, MA, and then as Principle Analytical Scientist and Director of Formulation Development at Inotek Pharmaceuticals, Beverly, MA, where he also was co-PI on a successful clinical program on sophisticated eye formulations for glaucoma.. He joined NAT as Head of Analytical Services in 2012, where he helped to develop an infrastructure of analytical operations and expand the range of services. Ken personally directed and conducted countless analytical projects, including HPCL method setup, development, and qualification, stability studies, dissolution study design and execution, particle size analysis, thermal analysis, etc. He is an outstanding problem solver in the analysis of various drug forms, including liposomal formulations and solid, semisolid and liquid formulation. Ken produced multiple high level formal reports that were a substantial part of CMC packages for clients’ IND application, and he participated in audits of GMP facilities engaged in procuring clinical grade APIs and drug products. Some of his other accomplishments are developing new chiral reactions for intermediates based on enzymatic and classical routes, being a key contributor on a new chiral technology platform, and scaling a new pharmaceutical intermediate to multi-kilo scale.
Benjamin Rivnay, Ph.D., Head of Formulation
Dr. Rivnay has over 30 years of R&D activity in a variety of positions in biomedicine, both in academia and in the biotechnology/pharmaceutical industry. Dr. Rivnay’s experience in test development and in the diagnostic industry started with research in the introduction of dozens of novel or improved clinical diagnostic tests in the field of women’s health, particularly in the area of infertility, at Repromedix Corporation, spanning a large variety of biological disciplines. His experience also includes activities to expand, upgrade and introduce new testing service capabilities in Formatech, Inc. (a drug formulation development CRO), focusing on physicochemical analytics and on tests for protein expression and purification. On the corporate management side, Dr. Rivnay served as VP of R&D at Repromedix and Director of R&D at Formatech Inc. At Repromedix, he oversaw the regulatory submission for approval of all testing services (CLIA) and served for over 12 years as Lab Director of a clinical diagnostic laboratory under GLP regulations. At Formatech Dr. Rivnay managed all of the drug formulation development activities for dozens of clients. This experience is essential for diagnostic kit/test development, as this type of activity is key to achieving long shelf life and stability of test performance over time. Subsequently, Dr. Rivnay served as Chief Scientist at Boston Therapeutics Inc, overseeing R&D activities that focused on a non-systemic drug for diabetes. Dr. Rivnay was recently involved in the Amphotericin B liposomal formulation study in a BAA contract from FDA/CDER/OGD/ORS.
Dr. Rivnay holds a Ph.D. in Biochemistry from and was Associate Professor at the Weizmann Institute of Science in Israel, and has published over 50 scientific articles.
Pierre Leblanc, Ph.D., Head of Biology
Dr. Pierre Leblanc is a biochemist with 20 years of academic and industrial experience in cellular and molecular immunology and biotechnology. His work has focused on studies of regulation and de-regulation of the immune response. He served as Director of Research at Oncogene Products and contributed to the development of novel antibody products and assay designs. He then joined Eikos, Inc. as Director of Molecular Biology and successfully managed several SBIR Phase I & II projects related to US Army-sponsored antimalarial drug development. He has recently carried out research at Shriners Hospital and Massachusetts General Hospital. Dr. Leblanc holds a Ph.D. degree in Biochemistry from McMaster University in Canada. He did postdoctoral research at Boston University and MIT.
Joseph Blanchard, Founder & Managing Director of Biotech Business Advisors LLC
Biotech Business Advisors is a specialty consulting firm that provides life science clients with expertise in corporate strategy, business development, fund raising and operations. Mr. Blanchard has over 20 years of leadership experience in the life science industry with companies involved in all facets of the field—drug development, diagnostics, analytical instrumentation, contract research and industrial biotechnology. Previously, Mr. Blanchard was Co-Founder and Chief Business Officer at Aushon BioSystems, Inc., a life science instrumentation company that markets innovative biomarker detection technology for use in drug development and diagnostic applications. He has also held senior management positions with other life science firms, including Genencor International (now owned by DuPont and previously #12 in revenues among biotechnology companies) and Altus Pharmaceuticals (a spin-off of Vertex Pharmaceuticals that had its IPO in 2006). Mr. Blanchard has also served on the board of directors and advisory boards of various drug development, diagnostic and contract research organizations. Joe has B.S. and M.B.A degrees from Miami University.